Literature DB >> 19578996

Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria.

Manuel Ramos-Casals1, Pilar Brito-Zerón, Marta Perez-De-Lis, Iratxe Jimenez, Maria-Jose Blanco, Albert Bove, Maria-Jose Soto, Miriam Akasbi, Candido Diaz, Juan Sentís, Antoni Siso.   

Abstract

The current 2002 classification criteria do not cover the broad clinical and immunological heterogeneity of primary Sjögren syndrome (SS), since five of the six criteria focus exclusively on glandular involvement and the remaining criterion is the mandatory presence of anti-Ro/La antibodies. The aim of this study was to analyze the clinical features of patients with a well-established diagnosis of primary SS who do not fulfill the 2002 classification criteria. Five hundred seven patients diagnosed with primary SS (1993 criteria) were consecutively included and followed up. Two hundred twenty-one (44%) patients did not fulfill the 2002 criteria. These patients were older at diagnosis (p < 0.001) and had a lower frequency of parotid enlargement (p = 0.002), fever (p = 0.041), arthritis (p = 0.041), vasculitis (p = 0.050), peripheral neuropathy (p = 0.002), cranial nerve involvement (p = 0.015), raised erythrocyte sedimentation rate ( ESR) levels (p < 0.001), anemia (p < 0.001), leukopenia (p = 0.037), hypergammaglobulinemia (p < 0.001), positive rheumatoid factor ( RF; p = 0.002), and cryoglobulinemia (p = 0.049) in comparison with those fulfilling 2002 criteria. However, there were no significant differences in the prevalence of sicca features, diagnostic tests, overall systemic involvement, antinuclear antibodies , complement levels, development of B-cell lymphoma, or survival. Patients with anti-Ro antibodies had the highest frequencies of systemic features, hematological abnormalities, and altered immunological markers. In conclusion, patients fulfilling the 2002 criteria, who have either a specific histological diagnosis (lymphocytic infiltration) or highly specific autoantibodies (Ro/La), might well be considered to have Sjögren "disease." In contrast, etiopathogenic mechanisms other than lymphocytic-mediated epithelial damage could be involved in patients with negative Ro and negative biopsy, in whom the term Sjögren "syndrome" seems more adequate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19578996     DOI: 10.1007/s12016-009-8152-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  33 in total

1.  Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992.

Authors:  P B Martens; S R Pillemer; L T Jacobsson; W M O'Fallon; E L Matteson
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

2.  Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome?

Authors:  R Manthorpe; C Benoni; L Jacobsson; Z Kirtava; A Larsson; R Liedholm; C Nyhagen; H Tabery; E Theander
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

Review 3.  Clinical manifestations and early diagnosis of Sjögren syndrome.

Authors:  Stuart S Kassan; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2004-06-28

Review 4.  Polarization of B effector cells in Sjögren's syndrome.

Authors:  Capucine Daridon; Thomas Guerrier; Valérie Devauchelle; Alain Saraux; Jacques-Olivier Pers; Pierre Youinou
Journal:  Autoimmun Rev       Date:  2007-02-08       Impact factor: 9.754

5.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

6.  Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity.

Authors:  E L Alexander; F C Arnett; T T Provost; M B Stevens
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

Review 7.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

Review 8.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

9.  Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome.

Authors:  P Tengnér; A K Halse; H J Haga; R Jonsson; M Wahren-Herlenius
Journal:  Arthritis Rheum       Date:  1998-12

10.  Linear epitopes of two different autoantigens-La/SSB and myelin basic protein--with a high degree of molecular similarity, cause different humoral immune responses.

Authors:  Apostolos G Terzoglou; John G Routsias; Constantinos Sakarellos; Maria Sakarellos-Daitsiotis; Haralampos M Moutsopoulos; Athanasios G Tzioufas
Journal:  J Autoimmun       Date:  2003-08       Impact factor: 7.094

View more
  14 in total

1.  Cutting-edge issues in organ-specific autoimmunity.

Authors:  M Eric Gershwin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 2.  Sjögren Syndrome and Other Causes of Sicca in Older Adults.

Authors:  Alan N Baer; Brian Walitt
Journal:  Clin Geriatr Med       Date:  2017-02       Impact factor: 3.076

Review 3.  Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults.

Authors:  Alan N Baer; Brian Walitt
Journal:  Rheum Dis Clin North Am       Date:  2018-08       Impact factor: 2.670

4.  The future of autoimmunity.

Authors:  Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

5.  Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up.

Authors:  Montserrat Núñez; Joaquim Fernández-Solà; Esther Nuñez; José-Manuel Fernández-Huerta; Teresa Godás-Sieso; Esther Gomez-Gil
Journal:  Clin Rheumatol       Date:  2011-01-15       Impact factor: 2.980

6.  Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.

Authors:  Andreina Manfredi; Marco Sebastiani; Stefania Cerri; Giulia Cassone; Pietrantonio Bellini; Giovanni Della Casa; Fabrizio Luppi; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2017-03-21       Impact factor: 2.980

7.  Vitamin D in "early" primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?

Authors:  Chiara Baldini; Andrea Delle Sedie; Nicoletta Luciano; Pasquale Pepe; Francesco Ferro; Rosaria Talarico; Chiara Tani; Marta Mosca
Journal:  Rheumatol Int       Date:  2013-10-06       Impact factor: 2.631

Review 8.  [Epidemiology of primary Sjörgren's syndrome].

Authors:  G Westhoff; A Zink
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

Review 9.  [Pathogenesis and diagnosis of Sjögren's syndrome].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

10.  The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients.

Authors:  Amira A Shahin; Sameh El-Agha; Ghada S El-Azkalany
Journal:  Clin Rheumatol       Date:  2014-03-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.